Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology...

The US FDA approved Akeega and Talvey late last week. Phase 3 trials validated Akeega's use in the treatment of patients with BRCA-positive prostate cancer. Talvey is...

Seeking to clear billions of dollars worth of litigation claiming that its iconic baby powder causes cancer, Johnson & Johnson has announced it is now prepared to offer a...

After failing yet again this week to overturn a judgment rejecting its plans to roll into a separate company more than 38,000 lawsuits claiming that its talc-based baby...

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board...

In its third fundraising round in less than two years, Hong Kong-listed globally active CDMO giant GenScript Biotech has netted a fresh $224 million capital injection...

Johnson & Johnson is finally pulling the plug on its iconic talc-based baby powder worldwide.

US health authorities are restricting the use of the Johnson & Johnson Covid vaccine somewhat belatedly, citing the rare blood clotting issues that have dogged this...